The Rise and Rise of Antibody-Drug Conjugates

The path of the "magic bullet" Around the turn of the last century, Paul Ehrlich postulated that tailored and targeted drug delivery might be a means of treating disease1. Some eighty years later,...
Learn More

Do Price and Value Assumptions Belong in a Target Product Profile?

We often get pushback from clients about the merit of including launch price assumptions and value proposition statements in the target product profile (TPP) for early-stage development programs....
Learn More

Maybe they should start calling it Decelerated Approval?

The FDA is proposing that a single trial could support both accelerated and full approval of oncology therapeutics. At first glance this seems to be a promising development. Though, as one reads more...
Learn More

Beyond rNPV Valuations

Many valuation purists believe that a risk-adjusted net present value (rNPV) is the be-all and end-all of the value of a pharmaceutical asset. After all, it captures all the best insights into future...
Learn More

Cancer Vaccines: Ready for Prime Time or Another False Dawn?

Cancer Vaccines: Ready for Prime Time or Another False Dawn? Moderna and BioNTech recently reported positive early clinical data for mRNA cancer vaccines in combination with PD-1/L1 inhibitors, so...
Learn More

Drug Repurposing: Realities and Roadblocks

Drug Repurposing Market: Realities and Roadblocks We receive a steady stream of enquiries about opportunities in drug repurposing, often from people who see a short, low risk pathway to large...
Learn More

The race is on: after almost six decades, RSV vaccines near the finish line

The COVID-19 pandemic established that, when push comes to shove, successful vaccine development and deployment can be conducted at breakneck speed, even when largely untried and untested...
Learn More

For pharma & biotech, what's the value of a valuation?

When a client approaches us about conducting a valuation for them, our first question is always: why? If, for example, the reason is to help support them in a partnering negotiation, we proceed...
Learn More

Targeted protein degradation: a new pharmacology paradigm?

Traditional drug development focuses on targeting proteins with a defined binding pocket or active site to regulate protein activity. These strategies have exploited only around 400 of the 4000...
Learn More

What Happens to Pharma Valuations as Interest Rates Rise?

Everyone familiar with the risk-adjusted net present value method (rNPV) knows automatically that valuations decrease as the discount rate increases. This is indeed a fundamental tenet of the...
Learn More

Targeted Radiotherapy: The Comeback Kid of Cancer Treatment?

The notion that a systemically administered source of radiation can be usefully directed towards a tumor has been exploited since the 1940s, when radioiodine was introduced as a treatment for thyroid...
Learn More

Light Due Diligence: A Contradiction in Terms?

Alacrita has established itself as an industry specialist in due diligence (DD), conducting over 25 DD assignments per year, across therapeutic areas and technologies. Sometimes a prospective clients...
Learn More
Previous
1 2 3 4 5 ... 6
Next

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2009-24 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.